Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 8, 2022 4:03 PM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone Life Sciences (Blackstone) has committed to make two pre-agreed milestone payments of $35m each to Autolus, totaling $70m. The milestones are expected to be recognized in Autolus Q4 2022 cash balance.
The first Blackstone milestone of $35m is being paid earlier than anticipated as a result of the joint steering committees review of Autolus interim analysis of pivotal FELIX Phase 2... More
Autolus Therapeutics (AUTL) announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 8, 2022 4:02 PM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the Phase 2 pivotal FELIX clinical trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint, based on a pre-planned interim analysis of 50 patients with morphological disease, as verified by an independent data monitoring committee (IDMC). The primary endpoint for the FELIX Phase 2 trial is the Overall Remission Rate (ORR), defined as the proportion of patients achieving Complete Remission (CR) and Complete Remission with Incomplete... More
